PMID- 22809684
OWN - NLM
STAT- MEDLINE
DCOM- 20130118
LR  - 20220318
IS  - 1573-2509 (Electronic)
IS  - 0920-9964 (Print)
IS  - 0920-9964 (Linking)
VI  - 140
IP  - 1-3
DP  - 2012 Sep
TI  - Impact on intracortical myelination trajectory of long acting injection versus 
      oral risperidone in first-episode schizophrenia.
PG  - 122-8
LID - 10.1016/j.schres.2012.06.036 [doi]
AB  - CONTEXT: Imaging and post-mortem studies suggest that frontal lobe intracortical 
      myelination is dysregulated in schizophrenia (SZ). Prior MRI studies suggested 
      that early in the treatment of SZ, antipsychotic medications initially increase 
      frontal lobe intracortical myelin (ICM) volume, which subsequently declines 
      prematurely in chronic stages of the disease. Insofar as the trajectory of ICM 
      decline in chronic SZ is due to medication non-adherence or pharmacokinetics, it 
      may be modifiable by long acting injection (LAI) formulations. OBJECTIVES: Assess 
      the effect of risperidone formulation on the ICM trajectory during a six-month 
      randomized trial of LAI (RLAI) versus oral (RisO) in first-episode SZ subjects. 
      DESIGN: Two groups of SZ subjects (RLAI, N=9; and RisO, N=13) matched on 
      pre-randomization oral medication exposure were prospectively examined at 
      baseline and 6 months later, along with 12 healthy controls (HCs). Frontal lobe 
      ICM volume was assessed using inversion recovery (IR) and proton density (PD) MRI 
      images. Medication adherence was tracked. MAIN OUTCOME MEASURE: ICM volume change 
      scores were adjusted for the change in the HCs. RESULTS: ICM volume increased 
      significantly (p=.005) in RLAI and non-significantly (p=.39) in the RisO groups 
      compared with that of the healthy controls. A differential between-group 
      treatment effect was at a trend level (p=.093). SZ subjects receiving RLAI had 
      better medication adherence and more ICM increases (chi-square p<.05). 
      CONCLUSIONS: The results suggest that RLAI may promote ICM development in 
      first-episode SZ patients. Better adherence and/or pharmacokinetics provided by 
      LAI may modify the ICM trajectory. In vivo MRI myelination measures can help 
      clarify pharmacotherapeutic mechanisms of action.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Bartzokis, George
AU  - Bartzokis G
AD  - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for 
      Neuroscience and Human Behavior, The David Geffen School of Medicine at UCLA, Los 
      Angeles, California, USA. gbar@ucla.edu
FAU - Lu, Po H
AU  - Lu PH
FAU - Raven, Erika P
AU  - Raven EP
FAU - Amar, Chetan P
AU  - Amar CP
FAU - Detore, Nicole R
AU  - Detore NR
FAU - Couvrette, Alexander J
AU  - Couvrette AJ
FAU - Mintz, Jim
AU  - Mintz J
FAU - Ventura, Joseph
AU  - Ventura J
FAU - Casaus, Laurie R
AU  - Casaus LR
FAU - Luo, John S
AU  - Luo JS
FAU - Subotnik, Kenneth L
AU  - Subotnik KL
FAU - Nuechterlein, Keith H
AU  - Nuechterlein KH
LA  - eng
GR  - MH037705/MH/NIMH NIH HHS/United States
GR  - R01 MH066029/MH/NIMH NIH HHS/United States
GR  - R01 AG027342/AG/NIA NIH HHS/United States
GR  - AG027342/AG/NIA NIH HHS/United States
GR  - R01 MH037705/MH/NIMH NIH HHS/United States
GR  - P50 MH066286/MH/NIMH NIH HHS/United States
GR  - MH6357/MH/NIMH NIH HHS/United States
GR  - MH 0266029/MH/NIMH NIH HHS/United States
GR  - MH51928/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120717
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
RN  - 0 (Antipsychotic Agents)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*administration & dosage
MH  - Case-Control Studies
MH  - Chi-Square Distribution
MH  - Drug Administration Routes
MH  - Drug Delivery Systems
MH  - Female
MH  - Follow-Up Studies
MH  - Frontal Lobe/*drug effects/pathology
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Nerve Fibers, Myelinated/*pathology
MH  - Patient Compliance
MH  - Psychiatric Status Rating Scales
MH  - Risperidone/*administration & dosage
MH  - Schizophrenia/*drug therapy/*pathology
MH  - Young Adult
PMC - PMC3567927
MID - NIHMS391169
COIS- Conflict of Interest All other authors declare that they have no conflicts of 
      interest.
EDAT- 2012/07/20 06:00
MHDA- 2013/01/19 06:00
PMCR- 2013/09/01
CRDT- 2012/07/20 06:00
PHST- 2012/03/23 00:00 [received]
PHST- 2012/06/21 00:00 [revised]
PHST- 2012/06/25 00:00 [accepted]
PHST- 2012/07/20 06:00 [entrez]
PHST- 2012/07/20 06:00 [pubmed]
PHST- 2013/01/19 06:00 [medline]
PHST- 2013/09/01 00:00 [pmc-release]
AID - S0920-9964(12)00353-2 [pii]
AID - 10.1016/j.schres.2012.06.036 [doi]
PST - ppublish
SO  - Schizophr Res. 2012 Sep;140(1-3):122-8. doi: 10.1016/j.schres.2012.06.036. Epub 
      2012 Jul 17.